Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Nasir Sadeghi, Zafar Siddiqui, Omer Iqbal, Schuharazad Abro, Debra Hoppensteadt, PhD, Michael Mosier, Jeanine Walenga, Jawed Fareed, PhD, Ahmed Kouta

Blood (2017) 130 (Supplement 1): 4868.

https://doi.org/10.1182/blood.V130.Suppl_1.4868.4868

Published: 2017

Journal Articles

Biochemical and Pharmacological Differentiation of APC and Recombinant Thrombomodulin with Reference to the Effect on the Hemostatic and Fibrinolytic Processes

Jawed Fareed, PhD, Debra Hoppensteadt, PhD, Walter Jeske, Omer Iqbal, Schuharazad Abro, Destini Clarizio, Sanchayana Raghuvir, Rachael Wasmund, Kosuke Tanaka, Kazuhisa Tsuruta

Blood (2017) 130 (Supplement 1): 4871.

https://doi.org/10.1182/blood.V130.Suppl_1.4871.4871

Published: 2017

Journal Articles

Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications

Zafar Siddiqui, Parul Aggarwal, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Mary Lewis, Schuharazad Abro, MD, Kazuhisa Tsuruta, PhD, Jawed Fareed, PhD

Blood (2016) 128 (22): 4974.

https://doi.org/10.1182/blood.V128.22.4974.4974

Published: 2016

Journal Articles

Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds

Jawed Fareed, PhD, Larissa Reikensmeyer, Amanda Walborn, BS, Debra Hoppensteadt, PhD, Jeanine M. Walenga, PhD, Eduardo Ramacciotti, MD, Schuharazad Abro, MD, Walter Jeske, PhD, Olivia Bouchard, Ismail Elalamy, MD PhD

Blood (2016) 128 (22): 3836.

https://doi.org/10.1182/blood.V128.22.3836.3836

Published: 2016

Journal Articles

International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation

Debra Hoppensteadt, PhD, Amanda Walborn, BS, Schuharazad Abro, MD, Michael Mosier, MD, Kazuhisa Tsuruta, PhD, Jawed Fareed, PhD

Blood (2016) 128 (22): 3797.

https://doi.org/10.1182/blood.V128.22.3797.3797

Published: 2016

Journal Articles

Dabigatran Neutralizing Antobody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications

Zafar Siddiqui, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Mary Lewis, Rohan Rege, Schuharazad Abro, MD, Jawed Fareed, PhD

Blood (2016) 128 (22): 2622.

https://doi.org/10.1182/blood.V128.22.2622.2622

Published: 2016

Journal Articles

Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188 ) As Studied in Agonist Induced Platelet Aggregation Systems

Nil Guler, MD, Schuharazad Abro, Martin Emanuele, PhD, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Jawed Fareed, PhD

Blood (2015) 126 (23): 1037.

https://doi.org/10.1182/blood.V126.23.1037.1037

Published: 2015

Journal Articles

Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation

Jawed Fareed, Ph.D., Debra Hoppensteadt, Ph.D., Omer Iqbal, MD, Schuharazad Abro, MD, Martin Emanuele, PhD

Blood (2013) 122 (21): 4770.

https://doi.org/10.1182/blood.V122.21.4770.4770

Published: 2013

Journal Articles

Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes

Schuharazad Abro, Melanie Clark, Marcus Quek, Omer Iqbal, MD, Daniel Kahn, Debra Hoppensteadt, Josephine Cunanan, MD, Jawed Fareed, PhD

Blood (2012) 120 (21): 3405.

https://doi.org/10.1182/blood.V120.21.3405.3405

Published: 2012

Journal Articles

Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents

Jawed Fareed, PhD, Debra Hoppensteadt, Omer Iqbal, MD, Josephine Cunanan, MD, Vinod Bansal, MD, Schuharazad Abro, Rakesh Wahi, MD

Blood (2012) 120 (21): 3411.

https://doi.org/10.1182/blood.V120.21.3411.3411

Published: 2012

Journal Articles

Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs

Soofia Masood, Debra Hoppensteadt, Josephine Cunanan, MD, Hussein Khan, Schuharazad Abro, Kimberly Bartosiak, Jawed Fareed, PhD

Blood (2012) 120 (21): 3421.

https://doi.org/10.1182/blood.V120.21.3421.3421

Published: 2012

NARROW

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Biochemical and Pharmacological Differentiation of APC and Recombinant Thrombomodulin with Reference to the Effect on the Hemostatic and Fibrinolytic Processes

Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications

Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds

International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation

Dabigatran Neutralizing Antobody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications

Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188 ) As Studied in Agonist Induced Platelet Aggregation Systems

Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation

Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes

Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents

Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only